speb/financial-data huggingface dataset:
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 155796767.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 12.99
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 3471000000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 427000000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 427000000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 158729412.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 12.75
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 2023800000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — EBIT: 2727200000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — EBITDA: 3154200000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 7468400000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 11100000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 11100000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Minority Interests: 0.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income: 2023800000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 2023800000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 2023800000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 2023800000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 2023800000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 2023800000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -11100000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -11100000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 3154200000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 2023800000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Operating Income: 2581700000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 10939400000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 145500000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 2516800000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 2716100000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 3471000000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 427000000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 692300000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.25
JBCHEPHARM.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 8357700000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — +Operating Expense: 4742500000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — +Total Revenue: 10849000000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 4097400000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 9377300000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 1077800000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 156373213.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Basic EPS: 13.29
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 335900000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 156600000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 937800000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 9013800000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Common Stock: 156600000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 38057400000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 321500000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 3454900000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Assets: 25551300000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 119100000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Debt: 73200000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 192300000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 6741700000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Provisions: 763600000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 444400000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 444400000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 158883792.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: 13.08
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 2078200000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — EBIT: 2805000000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — EBITDA: 3249400000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Goodwill: 574600000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 13305400000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 6786600000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Gross Profit: 7394100000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Interest Expense: 13500000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 13500000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Inventory: 5765800000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 38130600000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 1077800000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 216800000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 216800000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 259900000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Minority Interests: 0.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income: 2078200000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 2078200000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 2078200000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 2078200000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 2078200000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 2078200000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Net Interest Income: -13500000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -13500000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Net PPE: 6786600000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 24752000000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 75500000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 1832800000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 3249400000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Normalized Income: 2078200000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Operating Income: 2651600000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Operating Revenue: 10849000000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 156596239.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 1388500000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 329600000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 37900800000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 12730800000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 206000000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 15400000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 153400000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 2415500000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Properties: 6465100000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Receivables: 5900000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 8076000000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Payables: 4339900000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Pretax Income: 2791500000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 3454900000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 444400000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Share Issued: 156596239.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 38057400000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 24752000000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Tax Provision: 713300000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.26
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Assets: 47124000000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 38057400000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Debt: 409100000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 38057400000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-09-30) — Total Expenses: 8197400000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 9066600000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 21572700000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 2324900000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 242500000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2025-09-30) — Working Capital: 18809600000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 4848200000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 10647200000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 156682502.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 12.63
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 3294300000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 453500000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 453500000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 158947791.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 12.45
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 1978900000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — EBIT: 2687500000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — EBITDA: 3141000000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 7352900000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 18800000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 18800000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Minority Interests: 0.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income: 1978900000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 1978900000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 1978900000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 1978900000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 1978900000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 1978900000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -18800000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -18800000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 3141000000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 1978900000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Operating Income: 2504700000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 10647200000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 182800000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 2480500000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 2668700000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 3294300000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 453500000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 689800000.00
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.26
JBCHEPHARM.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 8142500000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — +Operating Expense: 18510168000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 4788600000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — +Total Revenue: 40761965000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 9042300000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 3909788000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 3909788000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 7809076000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 7809076000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Accumulated Depreciation: -8148868000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -8148868000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Additional Paid In Capital: 6360769000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 6360769000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -415439000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -415439000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Amortization: 926231000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 156864000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 156864000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 159637795.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 6.35
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 1150910000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Buildings And Improvements: 3371817000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 3371817000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -831887000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 35893000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 35893000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 160559000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 160559000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 1101822000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 1101822000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 12213473000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 12213473000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -3132926000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Cash Equivalents: 28800000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Cash Equivalents: 28800000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Cash Financial: 1073022000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Cash Financial: 1073022000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -1544475000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Change In Payable: -202674000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -565802000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -2312951000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Changes In Cash: -50547000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Common Stock: 160559000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 160559000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Common Stock Dividend Paid: -3132926000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 41592198000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 41592198000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Common Stock Issuance: 2319591000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 662329000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 662329000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 13243028000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 2742500000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Current Assets: 29093736000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 29093736000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 24646000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 24646000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Current Debt: 0.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 0.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 24646000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 24646000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 5911629000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 5911629000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 652693000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 652693000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Depreciation: 1824991000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 1824991000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 1824991000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 500100000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 898760000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 500100000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 160395570.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 6.32
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 7094747000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 1013700000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Dividends Payable: 29561000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Dividends Payable: 29561000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Dividends Received Cfi: 12000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — EBIT: 9577770000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — EBIT: 1359200000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — EBITDA: 11402761000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — EBITDA: 1859300000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Effect Of Exchange Rate Changes: 1459000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — End Cash Position: 1101822000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 260295000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 260295000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -1230969000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Finished Goods: 3332524000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Finished Goods: 3332524000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: 6207312000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -251757000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: -14172000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — General And Administrative Expense: 570297000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Goodwill: 574592000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Goodwill: 574592000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 12865610000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 12865610000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Gross Accounts Receivable: 8224515000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 8224515000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 14927405000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 14927405000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Gross Profit: 27518937000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 6299800000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Hedging Assets Current: 0.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Hedging Assets Current: 0.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Interest Expense: 54408000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 12300000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 54408000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 12300000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Interest Income: 337469000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Interest Income Non Operating: 337469000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -30423000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 97719000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Inventory: 6834030000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 6834030000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 41592198000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 41592198000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -5858777000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 417159000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 417159000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Issuance Of Capital Stock: 2319591000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Land And Improvements: 493076000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Land And Improvements: 493076000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 11247000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 11247000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 11247000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 11247000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 293700000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 293700000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Machinery Furniture Equipment: 9360590000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 9360590000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Minority Interest: 0.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Minority Interest: 0.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Minority Interests: 0.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Minority Interests: 0.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: 2319591000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: 200471000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Net Income: 7094747000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income: 1013700000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 7094747000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 1013700000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 7094747000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 1013700000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 7094747000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 1013700000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 7094747000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 1013700000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 9523362000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 7094747000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 1013700000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Net Intangibles Purchase And Sale: 0.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Net Interest Income: 281787000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -12300000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: -5143179000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: -138038000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: 281787000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -12300000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Net PPE: 6778537000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 6778537000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -813329000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Net Short Term Debt Issuance: -138038000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 28726588000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 28726588000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Revenue: 35817000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Revenue: 35817000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Assets: 68731000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 68731000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 1841844000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 1841844000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 293729000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 293729000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Non Current Prepaid Assets: 46267000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 46267000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 11409321000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 2131100000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Normalized Income: 7099634091.38
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 1218261333.43
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 7039199000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Operating Income: 9008769000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Operating Income: 1511200000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Operating Revenue: 40761965000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 9042300000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 160558706.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 160558706.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 1822300000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 1822300000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 330800000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 330800000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 41431600000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 41431600000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 12291018000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 12291018000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Other Inventories: 493926000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Inventories: 493926000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: -293539000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 2000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 2000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Other Non Current Liabilities: 35800000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 35800000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 6504000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 119800000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 3719181000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 2301200000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Other Payable: 880786000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Payable: 880786000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Other Properties: 1039593000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 1039593000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Other Receivables: 378776000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 378776000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 11111651000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 11111651000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Other Special Charges: 71020000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Other Special Charges: 84518000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Payables: 4912184000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Payables: 4912184000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Prepaid Assets: 1828820000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 1828820000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Pretax Income: 9523362000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 1346900000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Properties: 0.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: 215185000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Purchase Of Intangibles: 0.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: -23936158000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -831887000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Raw Materials: 2748349000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Raw Materials: 2748349000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 13243028000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 2742500000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 1824991000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 500100000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Rent And Landing Fees: 32123000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Rent Expense Supplemental: 32123000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Restricted Cash: 29561000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Restricted Cash: 29561000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Restructuring And Mergern Acquisition: 187282000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Restructuring And Mergern Acquisition: 187282000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Retained Earnings: 33286269000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 33286269000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 18792979000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 18558000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Selling And Marketing Expense: 4508833000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Selling General And Administration: 5079130000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Share Issued: 160558706.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 160558706.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Special Income Charges: -258302000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: -271800000.00
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Stock Based Compensation: 710103000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 41592198000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 41592198000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 28726588000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 28726588000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: -1672908.62
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -67238666.57
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Tax Provision: 2428615000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 333200000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.26
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.25
JBCHEPHARM.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -2562494000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Total Assets: 49686464000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 49686464000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 41592198000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 41592198000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Total Debt: 35893000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 35893000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 41592198000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 41592198000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Total Expenses: 31753196000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 7531100000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 8094266000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 8094266000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 20592728000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 20592728000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 2182637000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 2182637000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Total Other Finance Cost: 1274000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 92049000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 92049000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Total Unusual Items: -6560000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: -271800000.00
JBCHEPHARM.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: -6560000.00
JBCHEPHARM.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -271800000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Work In Process: 259231000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Work In Process: 259231000.00
JBCHEPHARM.NS balance_sheet (annual, 2026-03-31) — Working Capital: 23182107000.00
JBCHEPHARM.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 23182107000.00
JBDI income_statement (annual, 2021-05-31) — +Operating Expense: 5216000.00
JBDI income_statement (annual, 2021-05-31) — +Total Revenue: 9427000.00
JBDI balance_sheet (annual, 2021-05-31) — Accounts Payable: 650000.00
JBDI balance_sheet (annual, 2021-05-31) — Accounts Receivable: 1833000.00
JBDI balance_sheet (annual, 2021-05-31) — Accumulated Depreciation: -3157000.00
JBDI balance_sheet (annual, 2021-05-31) — Additional Paid In Capital: 1503000.00
JBDI balance_sheet (annual, 2021-05-31) — Allowance For Doubtful Accounts Receivable: -202000.00
JBDI cash_flow (annual, 2021-05-31) — Beginning Cash Position: 184000.00
JBDI cash_flow (annual, 2021-05-31) — Capital Expenditure: -8000.00
JBDI balance_sheet (annual, 2021-05-31) — Capital Lease Obligations: 1254000.00
JBDI balance_sheet (annual, 2021-05-31) — Capital Stock: 9000.00
JBDI balance_sheet (annual, 2021-05-31) — Cash And Cash Equivalents: 1247000.00
JBDI balance_sheet (annual, 2021-05-31) — Cash Cash Equivalents And Short Term Investments: 1247000.00
JBDI cash_flow (annual, 2021-05-31) — Cash Dividends Paid: -1361000.00
JBDI cash_flow (annual, 2021-05-31) — Cash Flow From Continuing Financing Activities: 318000.00
JBDI cash_flow (annual, 2021-05-31) — Cash Flow From Continuing Investing Activities: -8000.00
JBDI cash_flow (annual, 2021-05-31) — Cash Flow From Continuing Operating Activities: 697000.00
JBDI cash_flow (annual, 2021-05-31) — Change In Account Payable: -1027000.00
JBDI cash_flow (annual, 2021-05-31) — Change In Income Tax Payable: -77000.00
JBDI cash_flow (annual, 2021-05-31) — Change In Inventory: 76000.00
JBDI cash_flow (annual, 2021-05-31) — Change In Payable: -1104000.00
JBDI cash_flow (annual, 2021-05-31) — Change In Payables And Accrued Expense: -1104000.00
JBDI cash_flow (annual, 2021-05-31) — Change In Receivables: 61000.00
JBDI cash_flow (annual, 2021-05-31) — Change In Tax Payable: -77000.00
JBDI cash_flow (annual, 2021-05-31) — Change In Working Capital: -967000.00
JBDI cash_flow (annual, 2021-05-31) — Changes In Account Receivables: 61000.00
JBDI cash_flow (annual, 2021-05-31) — Changes In Cash: 1007000.00
JBDI balance_sheet (annual, 2021-05-31) — Common Stock: 9000.00
JBDI cash_flow (annual, 2021-05-31) — Common Stock Dividend Paid: -1361000.00
JBDI balance_sheet (annual, 2021-05-31) — Common Stock Equity: 2275000.00
JBDI income_statement (annual, 2021-05-31) — Cost Of Revenue: 2968000.00
JBDI balance_sheet (annual, 2021-05-31) — Current Assets: 3405000.00
JBDI balance_sheet (annual, 2021-05-31) — Current Capital Lease Obligation: 51000.00
JBDI balance_sheet (annual, 2021-05-31) — Current Debt: 682000.00
JBDI balance_sheet (annual, 2021-05-31) — Current Debt And Capital Lease Obligation: 733000.00
JBDI balance_sheet (annual, 2021-05-31) — Current Liabilities: 2034000.00
JBDI cash_flow (annual, 2021-05-31) — Depreciation: 421000.00
JBDI cash_flow (annual, 2021-05-31) — Depreciation Amortization Depletion: 421000.00
JBDI income_statement (annual, 2021-05-31) — Depreciation Amortization Depletion Income Statement: 469000.00
JBDI cash_flow (annual, 2021-05-31) — Depreciation And Amortization: 421000.00
JBDI income_statement (annual, 2021-05-31) — Depreciation And Amortization In Income Statement: 469000.00
JBDI income_statement (annual, 2021-05-31) — Depreciation Income Statement: 469000.00
JBDI income_statement (annual, 2021-05-31) — Diluted NI Availto Com Stockholders: 1111000.00
JBDI balance_sheet (annual, 2021-05-31) — Dueto Related Parties Current: 575000.00
JBDI income_statement (annual, 2021-05-31) — EBIT: 1284000.00
JBDI income_statement (annual, 2021-05-31) — EBITDA: 1753000.00
JBDI cash_flow (annual, 2021-05-31) — Effect Of Exchange Rate Changes: 56000.00
JBDI cash_flow (annual, 2021-05-31) — End Cash Position: 1247000.00
JBDI cash_flow (annual, 2021-05-31) — Financing Cash Flow: 318000.00
JBDI balance_sheet (annual, 2021-05-31) — Finished Goods: 256000.00
JBDI cash_flow (annual, 2021-05-31) — Free Cash Flow: 689000.00
JBDI balance_sheet (annual, 2021-05-31) — Gains Losses Not Affecting Retained Earnings: 2000.00
JBDI income_statement (annual, 2021-05-31) — General And Administrative Expense: 4479000.00
JBDI balance_sheet (annual, 2021-05-31) — Gross Accounts Receivable: 2035000.00
JBDI balance_sheet (annual, 2021-05-31) — Gross PPE: 6638000.00
JBDI income_statement (annual, 2021-05-31) — Gross Profit: 6459000.00
JBDI cash_flow (annual, 2021-05-31) — Income Tax Paid Supplemental Data: 55000.00
JBDI balance_sheet (annual, 2021-05-31) — Income Tax Payable: 75000.00
JBDI income_statement (annual, 2021-05-31) — Interest Expense: 41000.00
JBDI income_statement (annual, 2021-05-31) — Interest Expense Non Operating: 41000.00
JBDI cash_flow (annual, 2021-05-31) — Interest Paid Supplemental Data: 41000.00
JBDI balance_sheet (annual, 2021-05-31) — Inventory: 256000.00
JBDI balance_sheet (annual, 2021-05-31) — Invested Capital: 4331000.00
JBDI cash_flow (annual, 2021-05-31) — Investing Cash Flow: -8000.00
JBDI cash_flow (annual, 2021-05-31) — Issuance Of Debt: 1890000.00
JBDI balance_sheet (annual, 2021-05-31) — Land And Improvements: 1354000.00
JBDI balance_sheet (annual, 2021-05-31) — Long Term Capital Lease Obligation: 1203000.00
JBDI balance_sheet (annual, 2021-05-31) — Long Term Debt: 1374000.00
JBDI balance_sheet (annual, 2021-05-31) — Long Term Debt And Capital Lease Obligation: 2577000.00
JBDI cash_flow (annual, 2021-05-31) — Long Term Debt Issuance: 1890000.00
JBDI cash_flow (annual, 2021-05-31) — Long Term Debt Payments: -211000.00
JBDI balance_sheet (annual, 2021-05-31) — Machinery Furniture Equipment: 5061000.00
JBDI balance_sheet (annual, 2021-05-31) — Net Debt: 809000.00
JBDI income_statement (annual, 2021-05-31) — Net Income: 1111000.00
JBDI income_statement (annual, 2021-05-31) — Net Income Common Stockholders: 1111000.00
JBDI income_statement (annual, 2021-05-31) — Net Income Continuous Operations: 1111000.00
JBDI income_statement (annual, 2021-05-31) — Net Income From Continuing And Discontinued Operation: 1111000.00
JBDI income_statement (annual, 2021-05-31) — Net Income From Continuing Operation Net Minority Interest: 1111000.00
JBDI cash_flow (annual, 2021-05-31) — Net Income From Continuing Operations: 1243000.00
JBDI income_statement (annual, 2021-05-31) — Net Income Including Noncontrolling Interests: 1111000.00
JBDI income_statement (annual, 2021-05-31) — Net Interest Income: -41000.00
JBDI cash_flow (annual, 2021-05-31) — Net Issuance Payments Of Debt: 1679000.00
JBDI cash_flow (annual, 2021-05-31) — Net Long Term Debt Issuance: 1679000.00
JBDI income_statement (annual, 2021-05-31) — Net Non Operating Interest Income Expense: -41000.00
JBDI balance_sheet (annual, 2021-05-31) — Net PPE: 3481000.00
JBDI cash_flow (annual, 2021-05-31) — Net PPE Purchase And Sale: -8000.00
JBDI balance_sheet (annual, 2021-05-31) — Net Tangible Assets: 2275000.00
JBDI income_statement (annual, 2021-05-31) — Normalized EBITDA: 1753000.00
JBDI income_statement (annual, 2021-05-31) — Normalized Income: 1111000.00
JBDI cash_flow (annual, 2021-05-31) — Operating Cash Flow: 697000.00
JBDI income_statement (annual, 2021-05-31) — Operating Income: 1243000.00
JBDI income_statement (annual, 2021-05-31) — Operating Revenue: 9427000.00
JBDI balance_sheet (annual, 2021-05-31) — Ordinary Shares Number: 19787500.00
JBDI balance_sheet (annual, 2021-05-31) — Other Current Borrowings: 682000.00
JBDI balance_sheet (annual, 2021-05-31) — Other Current Liabilities: 1000.00
JBDI balance_sheet (annual, 2021-05-31) — Other Equity Adjustments: 2000.00